PD-1

GPTKB entity

Statements (68)
Predicate Object
gptkbp:instanceOf gptkb:protein
gptkbp:alternativeName gptkb:CD279
PDCD1
gptkbp:associatedWith gptkb:cancer
autoimmune diseases
chronic infections
gptkbp:blockadeSideEffect immune-related adverse events
gptkbp:blockadeUsedFor immunotherapy
gptkbp:contains IgV-like domain
gptkbp:discoveredBy gptkb:Tasuku_Honjo
gptkbp:discoveredIn 1992
gptkbp:encodedBy gptkb:PDCD1_gene
gptkbp:Entrez_Gene_ID ENSG00000188389
gptkbp:expressedIn gptkb:natural_killer_cells
gptkb:B_cells
gptkb:T_cells
monocytes
gptkbp:foundIn humans
mice
gptkbp:fullName gptkb:Programmed_cell_death_protein_1
gptkbp:function immunotherapy
inhibits T cell activity
gptkbp:gene PDCD1
gptkbp:HGNC_ID gptkb:HGNC:8765
https://www.w3.org/2000/01/rdf-schema#label PD-1
gptkbp:inhibitedBy cytokine production
T cell proliferation
T cell cytotoxicity
gptkbp:inhibitionLeadsTo enhanced immune response
gptkbp:ligand gptkb:PD-L2
PD-L1
gptkbp:locatedOnChromosome gptkb:2q37.3_(human)
gptkbp:mechanismOfAction inhibitory signaling via ITIM and ITSM motifs
gptkbp:OMIM 600244
gptkbp:PDB 3RRQ
gptkbp:phosphorylates Y223
Y248
gptkbp:regulates immune tolerance
peripheral tolerance
gptkbp:role immunotherapy
gptkbp:structure type I transmembrane protein
gptkbp:target gptkb:camrelizumab
gptkb:sintilimab
gptkb:tislelizumab
gptkb:toripalimab
gptkb:pembrolizumab
gptkb:cemiplimab
gptkb:nivolumab
gptkbp:UniProtID Q15116
gptkbp:bfsParent gptkb:Opdivo
gptkb:PD-L2
gptkb:immunoglobulin_superfamily
gptkb:PDCD1_gene
gptkb:camrelizumab
gptkb:sintilimab
gptkb:Tfh_cells
gptkb:programmed_death-ligand_1_(PD-L1)
gptkb:tislelizumab
gptkb:toripalimab
gptkb:Camrelizumab
gptkb:Nivolumab
gptkb:Sintilimab
gptkb:Tislelizumab
gptkb:Toripalimab
gptkb:CD279
gptkb:Libtayo
gptkb:cemiplimab
gptkbp:bfsLayer 7